An American from 19459004 could gain further access to a pioneering treatment in the future to prevent HIV from collecting.…
An American from 19459004 could gain further access to a pioneering treatment in the future to prevent HIV from collecting. The treatment, called Truvada for PrEP stops the spread of HIV in Australia, and researchers hope to test it in populations globally according to a new study.
RELATED: Do not Belive in Hype: Seven HIV / AIDS Myths We Need To Stop Believing
Truvada for PrEP or Pre-Exposure Prophylaxis – A term relating to the use of antiviral drugs that helps prevent HIV and AIDS – has been acclaimed as a game changer. New cases of HIV among gay and bisexual men decreased by almost one third to record record, according to recent research published by Australian researchers in the Lancet HIV Journal. New HIV infections fell from 1
49 to 102 in the state of New South Wales, Australia during the first year after the study began – an unprecedented reduction that gives a new hope to fight the virus that leads to AIDS.
Australian researchers investigated and measured the results of Truvada, an antiviral prescription drug made by Gilead Sciences Inc., which comes in the form of a blue pill, for the first time with the study.
“The rate of decline we have seen in new HIV infections in gay and bisexual men is the world’s first,” said study leader Andrew Grulich head of HIV epidemiology and prevention at Kirby Institute of University of New South Wales. “These figures are lowest on record since HIV surveillance began in 1985.”
The rate of infection among newly infected populations worldwide fell to 1.8 million world-wide in 2017, a drop of more than 3 million per years through most of the 1990s. African Americans saw a greater proportion of new HIV diagnoses compared to other races and ethnicities. By 2016, African Americans accounted for 44 percent of HIV diagnoses, although they comprised only 12 percent of the US population according to Centers for Disease Control and Prevention .
Truvada for PrEP, a fixed dose mixture of tenofovir, disoproxil and emtricitabine, has v Uxit in use for HIV prevention. About 180,000 people in the United States took Truvada for PrEP at the end of June, Robin L. Washington Gilead’s Chief Financial Officer, told Bloomberg in July. Areas most used by PrEP saw some of the best reductions in HIV infection, says Gilead’s Chief Executive Officer John F. Milligan .
It is unclear how and when researchers can further drive Truvada’s use in the United States but most likely that African Americans and other risk groups will try to take treatment.
Real Life Uncle Ruckus! Minister Jesse Lee Peterson: “Black people have been so violent over the years”
Frazzled White Woman calls the police on black children: “It’s like an uprising here!”